This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Isis' CEO Hosts To Review KYNAMRO Data Presented At The ESC 2012 Meeting Conference (Transcript)

Isis Pharmaceuticals, Inc. (ISIS)

Review KYNAMRO Data Presented at the ESC 2012 Meeting Conference Transcript

August 29, 2012 10:00 AM ET


Dr. Stanley Crooke - Chairman and CEO

Dr. Klaus Parhofer - Professor, Metabolism and Endocrinology, Ludwig-Maximilians University, Munich

Lynne Parshall - Chief Operating Officer

Rich Geary - Senior Vice President, Development

Walter Singleton - Vice President, Development and CMO

Wade Walke - Executive Director, Corporate Communications and IR


Nicholas Bishop - Cowen & Company

Stephen Willey - Stifel Nicolaus

Carol Werther - Summer Street

Chad Messer - Needham & Company

Sam Colin - First Manhattan Company



Good day, ladies and gentlemen. And welcome to Isis Pharmaceuticals' Conference Call to Review KYNAMRO Data that was recently presented at the ESC 2012 Meeting. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the conference over to Dr. Stanley Crooke, Chairman and CEO. Please proceed.

Dr. Stanley Crooke

Good morning, everyone. And thanks for joining us today. As [Donato] indicated the purpose of this call is to have Dr. Parhofer to review the additional results or some additional results on KYNAMRO that were presented at the European Society of Cardiology Meeting this morning in Munich.

Joining us on today’s call are Dr. Klaus Parhofer, Professor of Metabolism and Endocrinology at Ludwig-Maximilians University in Munich; Lynne Parshall, Chief Operating Officer; Rich Geary, Senior Vice President of Development; Walter Singleton, Vice President, Development and Chief Medical Officer; and Wade Walke, Executive Director, Corporate Communications and Investor Relations.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs